Double dose of good news for Lithium Australia


Published 27-FEB-2017 11:33 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Two important developments on Friday and Monday have resulted in Lithium Australia’s (ASX:LIT) share price surging approximately 14% when markets opened this morning.

Friday’s news could have gone unnoticed because it related to the first day’s trading in MetalsTech (ASX: MTC), an IPO which raised approximately $4.3 million at a price of 20 cents per share.

MTC closed at 27 cents on Friday, representing a premium of 35% to the IPO price.

It should be noted that share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

At listing date LIT held 2 million shares in MTC, as well as an existing agreement which provides significant equity and technology leverage across six highly prospective hard rock lithium projects in Québec.

The other important development that emerged on Monday was an advice by LIT Managing Director, Adrian Griffin, that litigation with Lepidico (ASX: LPD) subsidiary, Li-Technology Pty Ltd had been settled by mutual agreement.

Commercial details of the settlement are confidential, however Griffin stressed that the three registered L-Max licence agreements LIT has with Li-Technology remain valid and enforceable, being the exclusive L-Max licence for Western Australia, International Licence No.1 and International licence No.2.

Importantly, Lepidico has agreed that the 100% Lithium Australia owned proprietary Sileach process is not an improvement, enhancement or modification of the registered L-Max process.

In response to these developments, Griffin said, “Clearly the win removes distractions and paves the way for commercialising the Sileach process without legal impediment”.

This also represents a positive outcome for MTC as it holds a Sileach licence for operation in Québec.

Pilbara Minerals (ASX: PLS) is also a beneficiary as it has an agreement to work with LIT to commercialise Sileach for use on spodumene concentrates from its Pilgangoora project.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free